In Vivo Diagnosis Or In Vivo Testing Patents (Class 424/9.1)
  • Patent number: 11033620
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a microtubule inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 15, 2021
    Assignees: BIOMED VALLEY DISCOVERIES, INC., The United States of America, as Represented by the Secretary, Department of Health and Human Service National Institutes of Health
    Inventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
  • Patent number: 11034733
    Abstract: The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 15, 2021
    Assignee: Genome Protection, Inc.
    Inventor: Vadim Mett
  • Patent number: 11026610
    Abstract: A sensor implanted in tissues and including a sensing layer is fabricated by mixing the signal transduction enzyme with non-reactive components including buffer salts and fillers, and spin coating the enzyme onto a substrate. The signal transduction enzyme is crosslinked by introducing the coated substrate in a vacuum chamber. In the chamber, a crosslinker evaporates and is deposited onto the enzyme, therefore crosslinking the enzyme.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 8, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Samson Chen, Axel Scherer, Dvin Adalian, Peter Petillo, Muhammad Musab Jilani, Xiomara L. Madero, Deepan Kishore Kumar
  • Patent number: 11017207
    Abstract: Certain aspects of the present disclosure provide techniques for automatically detecting and classifying tumor regions in a tissue slide. The method generally includes obtaining a digitized tissue slide from a tissue slide database and determining, based on output from a tissue classification module, a type of tissue of shown in the digitized tissue slide. The method further includes determining, based on output from a tumor classification model for the type of tissue, a region of interest (ROI) of the digitized tissue slide and generating a classified slide showing the ROI of the digitized tissue slide and an estimated diameter of the ROI. The method further includes displaying on an image display unit, the classified slide and user interface (UI) elements enabling a pathologist to enter input related to the classified slide.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 25, 2021
    Assignee: Applied Materials, Inc.
    Inventors: Parijat Prakash Prabhudesai, Ganesh Kumar Mohanur Raghunathan, Sumit Kumar Jha, Aditya Sista, Narasimha Murthy Chandan
  • Patent number: 11013817
    Abstract: Provided herein are compositions, systems, kits, and methods for treating cancer in at least one bone of a subject using nanoparticles encapsulating, or conjugated to, an anti-cancer agent. In other embodiments, provided herein are composition, systems, kits, and methods for treating a bone disease (e.g., osteoporosis) in a subject using nanoparticle encapsulating, or conjugated to, a RANKL inhibitor. The nanoparticle are, in certain embodiments, neutral or nearly neutral in charge (e.g., zeta potential between ?5 and +5 mV) and less than 250 nm in diameter on average (e.g. have an average diameter between 100 and 200 nm).
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 25, 2021
    Assignee: The Cleveland Clinic Foundation
    Inventors: Vinod Labhasetwar, Isaac M. Adjei
  • Patent number: 11014966
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 25, 2021
    Assignee: CENTUARI THERAPEUTICS LIMITED
    Inventors: Melanie Glossop, Christine Watson, Michael Westby
  • Patent number: 11016089
    Abstract: A nanocomposite for detection and treatment of a target of interest including tumor cells or pathogens includes at least one nanostructure, each nanostructure having a core and a shell surrounding the core; a reporter assembled on the shell of each nanostructure; and a layer of a treating agent and a targeting agent conjugated to the reporter. In use, the nanocomposite targets to the target of interest according to the targeting agent and releases the treating agent and the nanostructure therein for therapeutic treatment of the target of interest, and the target of interest transmits at least one signature responsive to the reporter for detection of the target of interest.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 25, 2021
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Alexandru S. Biris, Zeid A. Nima
  • Patent number: 11013752
    Abstract: The present disclosure relates to compositions and methods for the regeneration and/or restoration of hair cells utilizing a composition or an agent that decreases expression of a gene in a tissue of the inner ear and a second agent.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 25, 2021
    Assignee: HOUGH EAR INSTITUTE
    Inventors: Matthew B. West, Richard D. Kopke
  • Patent number: 11017892
    Abstract: In one embodiment of the present disclosure, an ingestible medication device is a self-contained electronic device that stores an active agent, and that controls release of the active agent using an on board processor. The ingestible medication device embodies one or more ingestible device identifiers, including personal identifiers and active agent identifiers, which are compared with external device identifiers to determine whether to release the active agent. A method for managing an ingestible medication device detects proximity to a limited range, RFID-enabled patient wristband, indicating that the wristband is worn by the patient that ingested the ingestible medication device. Various methods enable a nurse to track medication information to monitor compliance with medication regimen and dosage information. Other methods track an ingestible medication device selected for filling a prescription at a pharmacy of the health care provider, including transfer to a caregiver station using a transport cart.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 25, 2021
    Assignee: Massachusetts Mutual Life Insurance Company
    Inventors: Michal Knas, Jiby John
  • Patent number: 11007277
    Abstract: A method of killing cells of a targeted cell type in a patient body that utilizes nanoparticles having a first portion, which when exposed to a target portion of a targeted cell type, binds to the target portion and a second portion, joined to the first portion, and comprised of a low resistivity material. The nanoparticles are introduced into a contact area where they contact cells of the targeted cell type. Contemporaneously, the contact area is exposed to a varying magnetic field of insufficient strength to increase the temperature of any part of the patient body by more than ten degrees Celsius, but which creates a current at the nanoparticles sufficient to disrupt function of the targeted cell type.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: May 18, 2021
    Inventor: Robert E. Sandstrom
  • Patent number: 11007272
    Abstract: Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for diagnosing and/or treating flaviviridae-family viruses including Zika virus, dengue virus, and yellow fever.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 18, 2021
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventors: Frederick O. Cope, David A. Ralph
  • Patent number: 11000580
    Abstract: Embodiments of the present invention concern methods of preventing malaria in a target population of humans comprising: uniformly administering a therapeutically effective amount of a live low dose malaria vaccine to each individual within the target population on each of two or three consecutive days. The methods include using Plasmodium infected mosquitoes to inject Plasmodium into individuals through mosquito bites.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: May 11, 2021
    Inventor: Eng Hong Lee
  • Patent number: 11000556
    Abstract: Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: May 11, 2021
    Assignee: Vedanta Biosciences, Inc.
    Inventors: Rose L. Szabady, Bernat Olle, Bruce Roberts
  • Patent number: 11000569
    Abstract: A medicament for use in treating fatty liver, hepatitis and cirrhosis, the medicament includes a marine algal glycoprotein.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 11, 2021
    Assignee: SHANDONG ZHONGHAI PHARMACEUTICAL CO. LTD
    Inventors: Qian Cheng, Baozhen Xu, Long Cheng
  • Patent number: 10987039
    Abstract: A microneedle array device includes a substrate and an array of microneedles on the substrate. Each microneedle includes a redox enzyme and redox mediator and an electrically conductive layer on the substrate. The electrically conductive layer may extend partway up each microneedle exposing the tip thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 27, 2021
    Assignee: STMICROELECTRONICS S.R.L.
    Inventors: Vincenza Di Palma, Maria Fortuna Bevilacqua, Andrea Di Matteo, Principia Dardano
  • Patent number: 10973847
    Abstract: Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 13, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Jeremiah A. Johnson, Matthew R. Golder
  • Patent number: 10967072
    Abstract: Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: April 6, 2021
    Assignee: Northwestern University
    Inventors: C. Shad Thaxton, Kaylin M. McMahon
  • Patent number: 10960067
    Abstract: The invention relates to a modified Neisseria lactamica, wherein the modified Neisseria lactamica is transformed with recombinant DNA encoding a heterologous protein; a method of prophylactic treatment for pathogenic infection of a subject comprising nasopharyngeal inoculation of a modified Neisseria lactamica; a method of reducing or preventing meningococcal colonisation of a subject; a method of modifying the microbiome of a subject; a wild-type Neisseria lactamica for use for the prophylactic treatment of meningococcal infection of a subject or reducing colonisation of a subject, wherein the prophylactic treatment comprises nasopharyngeal inoculation of the wild-type Neisseria lactamica; associated nucleic acid for mutagenesis of Neisseria lactamica; methods of mutagenesis; outer membrane vesicle (OMV) vaccines; and associated compositions and methods thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 30, 2021
    Inventors: Jay Robert Laver, Robert Charles Read
  • Patent number: 10960047
    Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 30, 2021
    Assignee: Lubris LLC
    Inventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
  • Patent number: 10953003
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 23, 2021
    Assignees: X4 PHARMACEUTICALS, INC., GENZYME CORP.
    Inventors: Paula Marie Ragan, Robert D. Arbeit, Kieran James Crowley
  • Patent number: 10947280
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 16, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • Patent number: 10940164
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Patent number: 10918743
    Abstract: The present invention relates to a liquid pharmaceutical composition including a complex of formula (I), in which M is an ion of a paramagnetic metal and R1 to R3, X1 to X3 and K1 to K12 are such as defined in claim 1, said composition also including a calcium complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The invention also relates to the preparation method thereof and to an imaging method involving said composition.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: February 16, 2021
    Assignee: GUERBET
    Inventors: Christelle Medina, Monique Sabatou, Anne Petit, Marc Port
  • Patent number: 10894097
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: January 19, 2021
    Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY AB
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • Patent number: 10888610
    Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 12, 2021
    Inventor: Per Bo Pedersen Fischer
  • Patent number: 10890531
    Abstract: Provided herein is an apparatus for assessing a fluorescence characteristic of a gemstone. The apparatus comprises an optically opaque platform for supporting a gemstone to be assessed, one or more light source to provide uniform UV and non-UV illumination, an image capturing component, and a telecentric lens positioned to provide fluorescent images of the illuminated gemstone to the image capturing component. Also provided are methods of fluorescence analysis based on images collected using such an apparatus.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: January 12, 2021
    Assignee: Gemological Institute of America, Inc. (GIA)
    Inventor: Hiroshi Takahashi
  • Patent number: 10869903
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: December 22, 2020
    Assignee: Evelo Biosciences, Inc.
    Inventors: David Berry, Noubar B. Afeyan, Johanne Kaplan, Neal Gordon, Shaila Rahman
  • Patent number: 10866239
    Abstract: The present disclosure provides methods of using certain biomarker expression profiles in the detection, diagnosis, prognosis, or development of treatment regimens for various cellular hyperproliferative disorders of the bowel. For example, pre-diagnostic methods comprise detecting whether the concentration of at least BAG4 in a test biological sample from a subject is elevated as compared to a control.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: December 15, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Paul Lampe, Junghyun Rho
  • Patent number: 10857190
    Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis conditions such as intestinal inflammation.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: December 8, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Sridhar Mani, Libusha Kelly, Hao Li
  • Patent number: 10857216
    Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: December 8, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, John P. Hennessey, Jr., Michael Timothy Cooke, Jack D. Sobel
  • Patent number: 10858497
    Abstract: A low viscosity polysulfide sealant composition. The composition comprises a curable polysulfide polymer; a crosslinking agent; and a plurality of core-shell particles. The core-shell particles comprise: a core comprising a ferromagnetic material; and a shell comprising silica treated with an organic sulfur containing compound. The shell is capable of bonding with the polysulfide polymer.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: December 8, 2020
    Assignee: THE BOEING COMPANY
    Inventors: Andrew P. Nowak, Sophia S. Yang, Thomas I. Boundy, Darrin M. Hansen, Alain A. Adjorlolo, Carissa A. Pajel, Eliana V. Ghantous
  • Patent number: 10857246
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 8, 2020
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Il Minn, Steven Rowe, Sangeeta Ray, Ronnie C. Mease, Michael Gorin, Mohamad Allaf, Martin G. Pomper
  • Patent number: 10858440
    Abstract: The invention provides anti-Jagged1 antibodies and methods of using the same.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: December 8, 2020
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
  • Patent number: 10851418
    Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: December 1, 2020
    Assignee: THE GEORGE WASHINGTON UNIVERSITY A CONGRESSIONAL CHARTERED NOT-FOR-PROFIT CORPORATION
    Inventors: Timothy A. Mccaffrey, Lakhmir S. Chawla
  • Patent number: 10849988
    Abstract: An immune-modulating biomaterial comprising a hydrogel scaffold coupled to D-amino acid containing peptides having unexpected properties in vivo is described. For example, certain inflammatory reactions in vivo are significantly increased around the D-peptide containing particles of hydrogel scaffold as compared to particles that contain both L and D peptides or L peptides alone. In addition, these D-peptide compositions are further observed to enhance wound healing and improve the tensile strength of healed tissues. For these and other reasons, the D-amino acid hydrogel materials disclosed herein are useful in a number of methodologies that seek to modulate the immune response and/or wound healing.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Tatiana Segura, Donald Griffin, Philip Scumpia
  • Patent number: 10829542
    Abstract: The invention relates to methods promoting the aggregation of Salmonella bacteria in the gut of subjects, thereby providing immune exclusion and limiting bacterial entry, therefore reducing mucosal and systemic infection.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 10, 2020
    Assignees: CSL BEHRING AG, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
    Inventors: Blaise Corthésy, Gilles Bioley, Cédric Pierre Vonarburg
  • Patent number: 10829524
    Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 10, 2020
    Assignee: Universiteit Utrecht Holding B.V.
    Inventors: Hendrik Peter Haagsman, Albert van Dijk, Edwin Johannes Adrianus Veldhuizen
  • Patent number: 10830767
    Abstract: A method of making at least one nanocomposite for surface enhanced Raman spectroscopy (SERS) detection of a target of interest includes forming at least one gold nanorod; coating a silver layer on an outer surface of the gold nanorod; assembling a Raman reporter molecule layer on the coated silver layer, wherein the Raman reporter molecule layer comprises Raman reporter molecules that are detectable by the SERS; coating a thiolated polyethylene glycol (PEG) layer on the assembled Raman reporter molecule layer; and conjugating the coated thiolated PEG layer with molecules of an antibody to make the at least one nanocomposite.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: November 10, 2020
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Alexandru S. Biris, Zeid Nima, Yang Xu
  • Patent number: 10830683
    Abstract: This disclosure provides a method for measuring coagulation of blood or plasma samples using viscoelastic tests (VET) wherein the measuring is performed in the presence of immobilised endothelial cells.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 10, 2020
    Assignee: C A Casyso GmbH
    Inventors: Heinz Redl, Johannes Zipperle, Wolfgang Holnthoner, Christoph Schlimp, Herbert Schochl
  • Patent number: 10822450
    Abstract: A method of preparing a polymeric material includes combining a glycerol-pharmaceutical conjugate, glycerol, and water in a vessel. The glycerol-pharmaceutical conjugate includes a pharmaceutical compound, for example, salicylic acid, having at least one carboxyl group attached to glycerol by an ester bond. The method also includes adding sebacic acid to the vessel and removing water from the vessel and reacting the glycerol, glycerol-pharmaceutical conjugate, and sebacic acid in the vessel at atmospheric pressure in the presence of an inert gas. The method further includes applying a sub-atmospheric pressure to the vessel after the step of reacting, to form the polymeric material in the vessel. The polymeric material includes a polyester copolymer of the sebacic acid and the glycerol and the pharmaceutical compound.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 3, 2020
    Assignee: THE SECANT GROUP LLC
    Inventors: Peter D. Gabriele, Carissa Smoot, Charles Brendan Nicholson, Jeremy J. Harris
  • Patent number: 10806913
    Abstract: The present invention concerns delivery of agents through the skin. Methods for delivering agents such as bioactive agents are contemplated by the present invention. Specifically, methods for the targeted delivery of agents to one or more areas of the epidermis and thereby, to one or more cancer tumors are described.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 20, 2020
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventor: Russell Frederick Ross
  • Patent number: 10806803
    Abstract: Provided are compounds and compositions for targeting macrophages and other CD206 high expressing cells.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 20, 2020
    Assignees: OHIO STATE INNOVATION FOUNDATION, CARDINAL HEALTH 414, LLC
    Inventors: Larry Schlesinger, Eric Bachelder, Frederick O. Cope
  • Patent number: 10799447
    Abstract: The present invention relates to methods of treating blepharitis and dry eye by inhibiting the binding ability of lid flora bacteria such as Staphylococcus aureus and Staphylococcus epidermidis, thus inhibiting biofilm formation and the increase in bacterial populations and densities that lead to quorum-sensing-gene activation and therefore, the production of inflammatory virulence factors.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 13, 2020
    Inventor: James M. Rynerson
  • Patent number: 10793889
    Abstract: Provided is a method of preparing nanoparticle-type polynucleotides, the method comprising forming the polynucleotides comprising modified nucleotides, in which the forming includes chemically synthesizing the polynucleotides comprising modified nucleotides, synthesizing the polynucleotides comprising modified nucleotides using an enzyme, or a combination thereof.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 6, 2020
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dae Ro Ahn, Kyoung Ran Kim
  • Patent number: 10793603
    Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 6, 2020
    Assignees: JOSHO GAKUEN EDUCATIONAL FOUNDATION, ADEKA CORPORATION
    Inventors: Shinji Sakuma, Kohta Mohri, Ken-ichiro Hiwatari, Kyohei Ochiai
  • Patent number: 10786582
    Abstract: Provided herein are compositions Gd(III)-dithiolane gold nanoparticle conjugates and methods of use thereof. In particular, compositions and method find use in in vivo imaging (e.g., magnetic resonance imaging (MRI)), for example, of pancreatic tissue.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: September 29, 2020
    Assignee: Northwestern University
    Inventors: Thomas J. Meade, Matthew W. Rotz, Robert J. Holbrook
  • Patent number: 10786579
    Abstract: Disclosed herein is the use of Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 29, 2020
    Assignee: Statens Serum Institut
    Inventors: Henrik Aggerbeck, Peter Lawætz Andersen, Morten Ruhwald
  • Patent number: 10780162
    Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: September 22, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Billy M. Hargis, Neil R. Pumford, Marion Morgan, Srichaitanya Shivaramaiah, Guillermo Tellez-Isaias, Amanda Wolfenden
  • Patent number: 10782295
    Abstract: Cells produce electrophilic products with the potential to modify and affect the function of proteins. Chemoproteomic methods have provided a means to qualitatively inventory proteins targeted by endogenous electrophiles; however, ascertaining the potency and specificity of these reactions to identify the most sensitive sites in the proteome to electrophilic modification requires more quantitative methods. Here, we describe a competitive activity-based profiling method for quantifying the reactivity of electrophilic compounds against 1000+ cysteines in parallel in the human proteome. Using this approach, we identify a select set of proteins that constitute hot spots for modification by various lipid-derived electrophiles, including the oxidative stress product 4-hydroxnonenal (HNE).
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: September 22, 2020
    Assignee: The Scripps Research Institute
    Inventors: Benjamin Cravatt, Chu Wang, Keriann Backus
  • Patent number: 10772534
    Abstract: A gastric emptying breath test method that includes collecting a breath sample of the subject at only a single time point after the subject consumes the breath test meal, wherein the single time point is a time point selected from within an identified time window.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 15, 2020
    Assignee: ADVANCED BREATH DIAGNOSTICS, LLC
    Inventor: Kerry C. Bush